Explore

Rapid Read Rapid Read
FDA Approves Pluvicto for Expanded Use in Metastatic Prostate Cancer

FDA Approves Pluvicto for Expanded Use in Metastatic Prostate Cancer

The U.S. Food and Drug Administration (FDA) has approved Pluvicto, a radioligand therapy developed by Novartis, for use in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC). This approval is based on the Phase III PSMAddition trial, which demonstrated that Pluvicto, in combination with standard care, significantly reduces the risk of disease progression or death. The therapy is now available for use across all stages of PSMA-positive metastatic prostate cancer, nearly doubling the eligible patient population. This marks a significant advancement in the treatment landscape for mHSPC, offering a new precision approach for early intervention.
Rapid Read Rapid Read
Scientists Propose Repurposing Glaucoma Drugs to Combat Aggressive Cancers

Scientists Propose Repurposing Glaucoma Drugs to Combat Aggressive Cancers

Researchers at The Institute for Cancer Research have discovered that drugs currently used to treat glaucoma could potentially be repurposed to combat aggressive cancers such as breast cancer, melanoma, and acute myeloid leukemia. The study identified a common molecular target, ROCK, which these cancers rely on to spread and become aggressive. By inhibiting this molecule, the drugs could potentially be used to treat these cancers. The research suggests that these existing drugs, already approved for glaucoma, could be fast-tracked into clinical trials for cancer treatment, potentially reaching patients more quickly. The study also identified specific markers that could help determine which patients might benefit from this treatment.
Rapid Read Rapid Read
Ohio State University Identifies New Target for Glioblastoma Treatment

Ohio State University Identifies New Target for Glioblastoma Treatment

Researchers at The Ohio State University Comprehensive Cancer Center have identified a potential new target for treating glioblastoma, one of the deadliest forms of brain cancer. The study, published in Cancer Letters, highlights the role of the protein SET in making glioblastoma cells more vulnerable to treatment. By suppressing SET, researchers found that tumor formation was prevented in preclinical models. The study also explored the role of PP2A, an enzyme that glioblastoma cells block through proteins like ANP32A, CIP2A, and SET. Blocking these proteins increased the cancer cells' sensitivity to radiation, suggesting a new pathway for drug targeting. The research is still in its early stages and has not yet been tested in human patients.
Rapid Read Rapid Read
VIRO 2026 Congress Highlights Advances in Renal Oncology Treatment Strategies

VIRO 2026 Congress Highlights Advances in Renal Oncology Treatment Strategies

The VIRO 2026 Congress, a global virtual medical event, is focusing on the latest advancements in renal oncology, particularly renal cell carcinoma and kidney cancer management. The congress gathers international experts to discuss current care standards, emerging treatment strategies, and practical approaches to improving patient outcomes. Renal cell carcinoma accounts for a significant number of cancer cases and deaths worldwide, with advanced stages posing treatment challenges. Recent therapeutic advancements, including immune checkpoint inhibitors and VEGF-targeted therapies, have reshaped care standards, though challenges remain in patient selection and long-term toxicity management.
Rapid Read Rapid Read
Moderna's mRNA Flu Vaccine Approved, Promising Enhanced Protection Against Influenza

Moderna's mRNA Flu Vaccine Approved, Promising Enhanced Protection Against Influenza

The Food and Drug Administration (FDA) has approved Moderna's mRNA flu vaccine, marking a significant advancement in public health. This new vaccine is expected to outperform the traditional flu vaccines that have been used for decades. The mRNA technology, which was pivotal in the development of COVID-19 vaccines, allows for faster production and better adaptation to the rapidly mutating flu virus. In clinical trials, the vaccine showed a 27% higher efficacy in preventing flu among older adults compared to standard vaccines. This development is seen as a breakthrough in addressing the flu, which causes millions of infections and hundreds of thousands of deaths annually.
Trendline Trendline
Verastem Oncology Reports Q2 2026 Financial Results and Advances Clinical Trials

Verastem Oncology Reports Q2 2026 Financial Results and Advances Clinical Trials

Verastem Oncology Reports Q2 2026 Financial Results and Advances Clinical Trials
Rapid Read Rapid Read
FDA Approvals Propel Cellular Gene Therapy Forward

FDA Approvals Propel Cellular Gene Therapy Forward

The FDA has approved over 40 cellular and gene therapy products, marking significant progress in the field. Recent approvals include treatments for rare genetic disorders and advancements in CAR T-cell therapy for cancer. The regulatory landscape is evolving to facilitate faster access to these therapies, which aim to provide curative solutions rather than just symptom management. The focus is on precision medicine, targeting the root causes of diseases with advanced genetic tools.
Rapid Read Rapid Read
Dana-Farber Cancer Institute Develops Platform for Discovering Molecular Glue Degraders

Dana-Farber Cancer Institute Develops Platform for Discovering Molecular Glue Degraders

Researchers at the Dana-Farber Cancer Institute have developed a novel platform for discovering molecular glues, which are compounds that can target and degrade disease-associated proteins previously considered undruggable. This platform leverages the ubiquitin-proteasome system to eliminate unwanted proteins by binding them to E3 ligases, which tag them for disposal. The study, published in Nature, highlights the potential of these molecular glues to expand the range of proteins that can be targeted for therapeutic purposes, particularly in cancer treatment. The platform has already led to the discovery of a metabolically activated molecular glue degrader, suggesting that these compounds could be more context-dependent and tunable than previously thought.
Rapid Read Rapid Read
Roswell Park Study Identifies Protein 'Switch' in Liposarcoma Aggressiveness

Roswell Park Study Identifies Protein 'Switch' in Liposarcoma Aggressiveness

Researchers at Roswell Park Comprehensive Cancer Center have identified a protein 'switch' that determines the aggressiveness of liposarcoma cells. Led by Dr. Blake Wilde, the study reveals that the protein PPAR-gamma influences whether stem-like cells in liposarcoma tumors develop into more aggressive or less aggressive forms. This discovery could lead to new treatment strategies for liposarcoma, a rare cancer that often recurs despite treatment. The research highlights the potential for targeting these stem-like cells to prevent the progression of manageable tumors into more dangerous forms.
The Columbus Dispatch The Columbus Dispatch
Ohio cyclospora parasite cases climb again as lettuce outbreak spreads

Ohio cyclospora parasite cases climb again as lettuce outbreak spreads

Cases of the parasite causing explosive diarrhea are now reported in almost every county in Ohio as the cyclosporiasis outbreak grows. See the numbers
USA Today USA Today
'Explosive' diarrhea outbreak expands. What are cases like in Georgia?

'Explosive' diarrhea outbreak expands. What are cases like in Georgia?

The cyclosporiasis outbreak traced to lettuce has expanded to 15 total states, CDC says. How many cases are there in Georgia right now?
Trendline Trendline
Plus Therapeutics Advances Cancer Treatment with Rhenium Obisbemeda

Plus Therapeutics Advances Cancer Treatment with Rhenium Obisbemeda

Plus Therapeutics Advances Cancer Treatment with Rhenium Obisbemeda